Insider Selling: Ingevity (NYSE:NGVT) SVP Sells $199,707.48 in Stock

Ingevity Corporation (NYSE:NGVT) SVP Ryan Fisher sold 2,709 shares of Ingevity stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $73.72, for a total transaction of $199,707.48. Following the completion of the transaction, the senior vice president owned 15,722 shares in the company, valued at approximately $1,159,025.84. This trade represents a 14.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Ingevity Stock Up 0.1%

Shares of Ingevity stock opened at $77.18 on Friday. The company has a market cap of $2.65 billion, a P/E ratio of 52.51 and a beta of 1.16. The company has a debt-to-equity ratio of 22.52, a quick ratio of 1.15 and a current ratio of 1.61. Ingevity Corporation has a one year low of $45.85 and a one year high of $79.29. The firm has a fifty day moving average of $72.37 and a two-hundred day moving average of $71.27.

Ingevity (NYSE:NGVT) last released its earnings results on Wednesday, July 29th. The company reported $1.74 EPS for the quarter, topping the consensus estimate of $1.33 by $0.41. The company had revenue of $314.10 million during the quarter, compared to analysts’ expectations of $312.20 million. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, analysts forecast that Ingevity Corporation will post 5.4 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Weiss Ratings raised Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, July 31st. Wall Street Zen cut Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 1st. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Ingevity currently has a consensus rating of “Hold” and a consensus price target of $80.00.

Institutional Trading of Ingevity

Several hedge funds and other institutional investors have recently made changes to their positions in NGVT. Global Retirement Partners LLC purchased a new stake in Ingevity during the fourth quarter worth about $27,000. Meeder Asset Management Inc. purchased a new position in Ingevity in the fourth quarter valued at about $33,000. Kestra Advisory Services LLC acquired a new stake in shares of Ingevity during the 4th quarter valued at approximately $47,000. Geneos Wealth Management Inc. boosted its stake in shares of Ingevity by 85.8% during the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after acquiring an additional 387 shares in the last quarter. Finally, Harbor Investment Advisory LLC purchased a new stake in shares of Ingevity during the 2nd quarter worth approximately $71,000. Institutional investors and hedge funds own 91.59% of the company’s stock.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.